Oral vs Injectable Retatrutide
As of September 2026, retatrutide is only being studied as a subcutaneous injectable. No oral formulation of retatrutide has been announced or entered clinical trials. Oral GLP-1 drugs exist (oral semaglutide/Rybelsus), but oral retatrutide is not currently in development.
How Retatrutide Is Administered
All Phase 2 and Phase 3 clinical trials for retatrutide use once-weekly subcutaneous injection. This is the only administration route with published human evidence.
Is There an Oral Retatrutide?
As of September 2026, Eli Lilly has not announced an oral retatrutide formulation in active clinical development. The oral GLP-1 class drug landscape includes oral semaglutide (Rybelsus, approved for T2D) and orforglipron (an oral GLP-1 agonist in Phase 3). Retatrutide is not among the oral formulations in this pipeline.
Online communities sometimes discuss "oral retatrutide" in the context of research peptide suppliers offering oral formulations. These are not clinically validated. The bioavailability of peptide drugs taken orally is generally very low without specific formulation technology.
Why Peptides Are Typically Injectable
Peptide drugs like retatrutide are typically administered by injection because they are degraded by digestive enzymes when taken orally. Oral bioavailability of unmodified peptides is very low. Oral semaglutide (Rybelsus) uses a specialized absorption enhancer (SNAC) to achieve oral bioavailability. No equivalent technology has been announced for retatrutide.
Questions about retatrutide? A licensed physician can review your case.
Start Physician Review